FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 17, 2025 (March 17, 2025)
BridgeBio Pharma, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
001-38959
|
84-1850815
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
3160 Porter Dr., Suite 250
|
|
|
|
Palo Alto, CA
|
|
94304
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (650) 391-9740
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
|
BBIO
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective
Date”). In connection with Dr. Stephenson’s transition from the Company, pursuant to and subject to the terms of the employment offer letter agreement, dated October 26, 2018, as amended on February 21, 2024, between Dr. Stephenson and BridgeBio
Services, Inc., a wholly-owned subsidiary of the Company, Dr. Stephenson will be entitled to (i) a lump sum payment equal to nine (9) months of his current base salary and (ii) up to nine (9) months of COBRA reimbursements. In addition, on the
Effective Date, the Company entered into a consulting agreement (the “Consulting Agreement”) with Dr. Stephenson, pursuant to which Dr. Stephenson will provide services to the Company as a consultant from the Effective Date through March 17, 2026,
unless earlier terminated pursuant to the terms of the Consulting Agreement.
The foregoing summary of the Consulting Agreement is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which
will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2025 and incorporated herein by reference.
| Item 7.01 |
Regulation FD Disclosures.
|
On March 17, 2025, the Company issued a press release announcing the appointment of Thomas Trimarchi, Ph.D. as President and Chief Financial Officer of
the Company and Dr. Stephenson’s transition from the Company. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act
or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
Number
|
|
Description of Exhibit
|
| |
|
|
|
|
|
Press Release dated March 17, 2025.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
BridgeBio Pharma, Inc.
|
| |
|
|
Date: March 17, 2025
|
|
| |
Neil Kumar, Ph.D.
|
| |
Chief Executive Officer
|
